By Reuters
NYT U.S.
Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient.
Published date: June 29, 2020 at 02:28PM
Reuters
New York Times article
No comments:
Post a Comment